

Contents

1.	Basics	13
1.1.	Bubbles and how ultrasound systems talk to them (P.N. Burns)	13
1.1.1.	Contrast agents for ultrasound	14
1.1.1.1.	Blood pool agents	14
1.1.1.2.	Selective uptake agents	15
1.1.2.	Talking to bubbles: physical principles of contrast imaging	16
1.1.2.1.	Bubble behavior and incident pressure	16
1.1.2.2.	The Mechanical Index (MI)	16
1.1.2.3.	Nonlinear echoes and harmonic imaging	17
1.1.2.4.	Harmonic B-mode imaging	18
1.1.2.5.	Pulse inversion imaging	18
1.1.2.6.	Pulse inversion Doppler imaging: amplitude and phase modulation	19
1.1.2.7.	Temporal Maximum Intensity Projection (MIP) imaging	20
1.1.2.8.	Disrupting bubbles: intermittent imaging	20
1.1.3.	References	21
1.2.	Safety considerations and regulatory status (P.N. Burns)	23
1.2.1.	References	25
1.3.	Clinical aspects of severe adverse reactions (M. Höpfner)	26
1.3.1.	References	26
1.4.	CEUS image documentation (L. Thorelius)	27
1.4.1.	CEUS and the time factor	27
1.4.2.	Documentation basics	27
1.4.3.	Characterization of FLL's	27
1.4.4.	Detection of liver metastases	28
1.4.5.	Non-liver CEUS documentation	31
1.5.	Examination strategies, tips & techniques (H.-P. Weskott)	31
1.5.1.	Prior to a CEUS study	31
1.5.2.	Reasons for an insufficient contrast enhancement	33
1.5.3.	Dosage of contrast agent	35
1.5.4.	Acoustic output (MI) and bubble destruction	36
1.5.5.	Probe types and contrast imaging	37
1.5.6.	CEUS performance	39
1.5.7.	References	43
2.	Liver	44
2.1.	Kinetics of US contrast agents (H.-P. Weskott)	44
2.2.	Benign focal liver lesions (K.F. Stock)	45
2.2.1.	Benign cystic liver lesions	46
2.2.2.	Focal fatty infiltration	46
2.2.3.	Hemangioma	47
2.2.4.	Focal nodular hyperplasia	48
2.2.5.	Hepatic adenoma	50
2.2.6.	Rare benign focal liver lesions	52
2.2.7.	References	52
2.3.	Infectious diseases (L. Thorelius)	54
2.3.1.	Liver infections	54
2.3.2.	Liver abscesses	54
2.3.3.	Renal infections	56
2.3.4.	Infections elsewhere	57

2.3.5.	Endocavitary CEUS	58
2.4.	Hepatocellular carcinoma (R. Lencioni, C. Della Pina, L. Crocetti)	58
2.4.1.	Introduction	58
2.4.2.	Ultrasound and Contrast-enhanced Ultrasound	59
2.4.3.	Diagnostic work-up	62
2.4.4.	References	63
2.5.	Cholangiocarcinoma (C. Pachmann)	65
2.5.1.	References	67
2.6.	Detection of focal liver lesions (H.-P. Weskott)	68
2.6.1.	References	71
2.7.	Differentiation between benign and malignant liver lesions (H.-P. Weskott)	72
2.7.1.	References	77
2.8.	Evaluation and characterization of metastatic liver disease (H.-P. Weskott)	77
2.8.1.	Vascular involvement	82
2.8.2.	References	86
2.9.	The role of contrast enhanced ultrasound in liver surgery (E. Leen, G. Low)	86
2.9.1.	Introduction	86
2.9.2.	Background	87
2.9.3.	Contrast enhanced intraoperative US (CE-IIOUS) technique	88
2.9.4.	Characterization of focal liver lesions with CE-IIOUS	89
2.9.5.	CE-IIOUS of liver metastases	90
2.9.6.	Actual change in surgical management as a result of CE-IIOUS	91
2.9.7.	Clinical perspective	91
2.9.8.	CE-IIOUS of HCC	92
2.9.9.	Limitations of CE-IIOUS	94
2.9.10.	Future directions and challenges	94
2.9.11.	References	94
2.10.	Evaluation of anti-angiogenic treatments using dynamic contrast-enhanced ultrasonography with quantification (N. Lassau, L. Chami, M. Chebil)	97
2.10.1.	Post processing	98
2.10.2.	Further evaluation of DCE-US	98
2.10.3.	References	105
3.	Gallbladder diseases (H.-P. Weskott)	107
3.1.	Cholecystitis and complications	107
3.2.	Malignant tumors of the gallbladder wall	111
3.3.	References	112
4.	Pancreas	114
4.1.	Pancreatic vasculature and parenchymal enhancement (M. D'Onofrio, A. Gallotti, R.P. Mucelli)	114
4.2.	Comparison to other imaging modalities (M. D'Onofrio, A. Gallotti, R.P. Mucelli)	114
4.3.	Examination technique (M. D'Onofrio, A. Gallotti, R.P. Mucelli)	116
4.4.	Inflammatory diseases (M. D'Onofrio, A. Gallotti, R.P. Mucelli)	116
4.5.	Cystic tumors (M. D'Onofrio, A. Gallotti, R.P. Mucelli)	117
4.6.	Solid pancreatic tumors (C. Pachmann)	119
4.7.	References	122
5.	Spleen (C. Görg)	125
5.1.	Splenic vasculature and parenchymal enhancement	125

5.2.	Examination technique	125
5.3.	Diffuse splenic diseases	126
5.4.	Vascular splenic lesions	129
5.5.	Benign focal lesions	131
5.6.	Secondary malignant focal splenic lesions	134
5.7.	References	135
6.	Kidneys and collective system	137
6.1.	Infectious diseases (H.-P. Weskott)	137
6.2.	Solid renal tumors (H.-P. Weskott)	141
6.2.1.	Benign renal tumors	143
6.2.1.1.	Angiomyolipoma	143
6.2.1.2.	Oncocytoma	146
6.2.2.	Malignant renal tumors	148
6.3.	Cystic renal tumors (H.-P. Weskott)	153
6.3.1.	Urothelium carcinoma	156
6.3.2.	Renal lymphomas	158
6.3.3.	References (Chapter 6.1.-6.3.)	159
6.4.	Disorders of the renal blood supply (K.F. Stock, H.-P. Weskott)	161
6.4.1.	References	165
6.5.	Transplant kidney (K.F. Stock)	166
6.5.1.	References	169
6.6.	Monitoring of tumor treatment: CEUS in the management of thermal ablation in renal cell cancer (D. Clevert)	170
6.6.1.	Introduction	170
6.6.2.	Pre-Interventional, peri-interventional and follow-up imaging and the potential of Contrast-Enhanced Ultrasound (CEUS)	171
6.6.3.	References	175
7.	Abdominal aortic pathologies and follow up after endovascular aneurysm repair (EVAR) (D. Clevert)	177
7.1.	Normal abdominal aortic anatomy	177
7.2.	Abdominal aortic aneurysm (AAA)	177
7.3.	Aortic dissections	178
7.4.	Aorto-caval fistulas	180
7.5.	Inflammatory abdominal aortic aneurysm	180
7.6.	Endovascular aneurysm repair (EVAR)	182
7.7.	References	185
8.	Neovascularization of the vessel wall: Role and diagnostic approach to neovascularization in vascular disease (H.-P. Weskott)	188
8.1.	Examination technique	188
8.2.	CEUS in arterial lumen imaging	189
8.3.	Vessel wall and the process of vascularization	190
8.4.	References	194